This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    SMILE | Heart Failure
Previous Study | Return to List | Next Study

Sensible Medical Innovations Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure Patients (SMILE™)

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by Sensible Medical Innovations Ltd.
Sponsor:
Information provided by (Responsible Party):
Sensible Medical Innovations Ltd.
ClinicalTrials.gov Identifier:
NCT02448342
First received: May 10, 2015
Last updated: June 1, 2017
Last verified: June 2017
  Purpose
Multi center, randomized controlled study, to determine if a significant decrease in the rate of heart failure re-hospitalizations occurs during a follow-up period when - ReDS guided treatment is used as an adjunct to standard of care.

Condition Intervention
Heart Failure Device: Remote Dielectric Sensing (ReDS) Wearable System

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Prevention
Official Title: Sensible Medical Innovations (Noninvasive) Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure Patients- a Randomized Controlled Study

Resource links provided by NLM:


Further study details as provided by Sensible Medical Innovations Ltd.:

Primary Outcome Measures:
  • The rate of recurrent events of HF readmissions [ Time Frame: Entire follow-up period (Expected average of 6.5 months) ]

Secondary Outcome Measures:
  • Time from discharge until the first event of HF readmissions [ Time Frame: Time to event (from discharge until the date of first event of HF readmissions, assessed up to 6.5 months) ]
  • Proportions of total days lost to hospitalization due to HF events [ Time Frame: Entire follow-up period (Expected average of 6.5 months) ]
  • Time from discharge until all-cause mortality [ Time Frame: time to event (from time of discharge until the date of first event of HF readmissions, assessed up to 6.5 months) ]

Estimated Enrollment: 380
Study Start Date: August 2015
Estimated Study Completion Date: September 2017
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ReDS Guided Treatment
After discharge from hospital, patient will perform daily ReDS measurement. Data is automatically transmitted to the secured web portal. Treating physician will follow up on patients' measurements through a secured dedicated web site. Notification messages will be automatically sent by the system to the physician if certain thresholds are crossed (thresholds are physician adjustable). Medications will be adjusted according to defined guidelines. During the study a service center will monitor and support patient adherence and investigators attending to patients' notifications.
Device: Remote Dielectric Sensing (ReDS) Wearable System
The ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.
Other Names:
  • ReDS
  • Wearable Vest
Active Comparator: Standard of Care- Control arm
After discharge from hospital, patient will be followed up and medically managed according to standard of care guidelines.
Device: Remote Dielectric Sensing (ReDS) Wearable System
The ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.
Other Names:
  • ReDS
  • Wearable Vest

Detailed Description:

The study is designed as a prospective, randomized, controlled, multi-center trial. Patients will be enrolled during an index hospitalization for Acutely decompensated Heart Failure (ADHF) and will be followed for a minimum of 3 months or a maximum of 9 months (until the last patient has completed the 3- month follow-up). Patients will be blinded to ReDS readings values.

Recruitment will take place either during a heart failure hospitalization (see acceptance criteria below) or within 10 days after discharge from a qualifying heart failure hospitalization.

The Remote Dielectric Sensing (ReDS) device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.

Study objective is to determine if a significant decrease in the rate of heart failure re-hospitalizations occurs during the entire follow-up period when ReDS guided treatment is used as an adjunct to standard of care (SOC).

Patients will be randomized between two groups before hospital discharge to: ReDS with SOC vs. SOC.

Patient that are randomized to the treatment arm will perform daily ReDS measurement at home. Treating physician will follow up on patients' measurements through a secured dedicated web site. Notification messages will be automatically sent by the system to the physician if certain thresholds are crossed (thresholds are physician adjustable). Medications will be adjusted according to defined guidelines.

Patients that are randomized to the control arm will be followed up and medically managed according to standard of care guidelines.

Both arms scheduled clinical visits and phone follow up:

  • A follow up phone call, per current treatment guidelines, will be attempted within 2 days of hospital discharge to obtain information regarding medication reconciliation, Heart Failure (HF) symptoms and other HF management issues (e.g., dietary restrictions).
  • An outpatient clinic visit will be scheduled after a week of hospital discharge.
  • Study follow-up visits at 1 and 3 months. Follow-up will be continued for enrolled subjects at 6 and 9 months until the last subject has pass through the 3-month follow-up window.

    • At each study follow-up visit, patients will undergo complete physical exam, vital signs, collection of readmission and standard blood tests and QOL questionnaire.
  Eligibility

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  1. Patient has signed informed consent and authorization to use and disclose health information.
  2. Patient's physical condition enables him to sit up and lay down with minimal assistance.
  3. Diagnosis of HF, with preserved or reduced LVEF, was made at least 30 days prior to enrollment.
  4. Patients with LVEF <40% must have been treated at least 30 days prior to enrollment with diuretics and beta-blocker (unless intolerant or contra-indicated) and an ACE-inhibitor or ARB (unless intolerant or contra-indicated).
  5. Patient is hospitalized for ADHF requiring significant alteration in heart failure treatment (i.e. diuretics or vasoactive drugs) or up to 10 days post-discharge from an ADHF admission.
  6. BNP ≥ 350 pg/ml (NT pro BNP > 1400 pg/ml) at enrollment (within 24h) and/or ≥750 pg/ml any time during the hospital stay (NT-pro BNP >3000 pg/ml).

Note that if a patient is enrolled during a clinic visit rather than during a hospitalization, then the BNP from the index admission is referenced.

Main Exclusion Criteria:

  1. Patient has had a cardiac transplantation or VAD implantation.
  2. CRT implantation within 90 days prior to screening or planned implantation during study duration.
  3. Current or past Pulmonary Embolism in the right lung. Notes: (i) Past pulmonary emboli are defined as identified <6 months prior to enrollment. (ii) past or current tiny, microscopic pulmonary emboli do not exclude a patient. (iii) if a ventilation-perfusion (VQ) scan shows that the lungs are clear, then the exclusion criteria is not met.
  4. Diagnosis of Severe Pulmonary Hypertension.
  5. STEMI and or CABG within 30 days of screening visit. Note: Type 2 MI due to ADHF is not an exclusion.
  6. Chronic renal failure with CrCl<25mL/min, as calculated by the Cockcroft-Gault formula.
  7. Chronic home IV therapy or cardiac inotropes or diuretics
  8. Physical deformity in the thorax area or lesion that may prevent proper vest application or adjustment (Severe scoliosis/ sensitive sternotomy lesion etc.).
  9. Illness/ Condition which may be aggravated or cause significant discomfort by the application of the vest (Rib fractures, with or without flail chest, Severe Osteoporosis).
  10. Impaired cognitive ability or any other state that may prevent full compliance with the study protocol, according to investigator's assessment.
  11. Patient's habitus out of range due to one or more of the following:

    • Height less than 155cm or higher than 195cm (5.1; 6.4 feet respectively).
    • BMI of less than 22 or more than 36. In case of BMI between 36-38, if the measured vest ruler is not >=4, the exclusion criteria is met.
  12. Congenital heart malformations or intra-thoracic mass that would affect the right lung anatomy (Dextrocardia, Lung Carcinoma etc.) including pacemaker box on the right side of the chest.
  13. Severe COPD, defined as chronic and continuous home use of O2 (O2 dependancy) and/ or oral steroids. Continuous is defined as 24hours a day, every day.
  14. Severe disease / conditions with life expectancy <6 months according to investigator's assessment.
  15. Patient is enrolled in another interventional study with permission of study manager (observational or registries are not excluded).
  16. Patient HF is managed remotely with another monitoring device or program (for example: Pulmonary/ Lt Atrial pressure monitoring, Weight scale, BNP or bioimpedance).
  17. Prisoners and ward of the state
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02448342

Contacts
Contact: Marci Mishkin (917) 403-9058 marci.m@sensible-medical.com
Contact: William Tobin (203) 895 7440 billt@ihcresearch.com

  Show 41 Study Locations
Sponsors and Collaborators
Sensible Medical Innovations Ltd.
Investigators
Principal Investigator: William Abraham, MD Ohio State University
Study Director: Aharon (Ronnie) Abbo, MD Sensible Medical Innovations Ltd.
  More Information

Additional Information:
Publications:
Responsible Party: Sensible Medical Innovations Ltd.
ClinicalTrials.gov Identifier: NCT02448342     History of Changes
Other Study ID Numbers: CL-00100-P
Study First Received: May 10, 2015
Last Updated: June 1, 2017

Keywords provided by Sensible Medical Innovations Ltd.:
Heart Failure
Remote Patient Monitoring
Non Invasive Lung Fluid Status Monitor

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on July 21, 2017